Robert E Ivy insider trades: Sonus Pharmaceuticals (SNUS) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Robert reports to the SEC
Open-market buys and sales
1 trade reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| May 18, 2007 | SNUS | ↓ Sell10b5-1 | 30,000 | $5.41 | $162K | Direct | May 18, 2007 (0d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About Robert E Ivy's insider trades
Robert E Ivy is a director at Sonus Pharmaceuticals (SNUS). Since May 18, 2007, Robert has reported no open-market purchases and 1 sale worth $162K on SEC Form 4. There have been no open-market trades in the last 12 months.
1 sale (100% of the value sold) was made under a Rule 10b5-1 trading plan, which is set up months in advance and runs on a schedule, so it says little about how the insider sees the stock today.
Their filings also include grants and awards (3 filings), option exercises (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every SNUS insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.